ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Costabel, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Costabel, U.
Eur Respir J 2001; 18:56S-68S
Copyright ©ERS Journals Ltd 2001


Sarcoidosis: clinical update

U. Costabel

CORRESPONDENCE: U. Costabel, Ruhrlandklinik, Dept Pneumology/Allergology, Tueschener Weg 40, 45239, Essen, Germany. Fax: 49 2014334029

Keywords: bronchoalveolar lavage, CD4/CD8 ratio, corticosteroids, Löfgren's syndrome, sarcoidosis

Received: March 8, 2001
Many advances have been made regarding sarcoidosis in the past 2 decades. As a result, sarcoidosis is now defined as a multisystem disorder with a heightened cellular immune response at sites of disease activity in patients with a predisposition for sarcoidosis and a presumed exposure to as yet unknown transmissible environmental agents.

Recent International Consensus Statement recommendations regarding diagnosis and therapy have been published. The diagnosis of sarcoidosis is based on a compatible clinical and/or radiological picture, histological evidence of noncaseating granulomas and exclusion of other diseases capable of producing a similar histological or clinical picture.

Therapy is based on corticosteroids, although there are indications of valuable alternatives. Except for life- and sight-threatening organ involvement, it should be carefully considered whether the patient might benefit from treatment. For asymptomatic pulmonary sarcoidosis, a watch and wait approach is appropriate; treatment should mainly be considered if symptoms develop or lung function deteriorates.




This article has been cited by other articles:


Home page
Eur Respir JHome page
B. J. Plant, S. Ghani, M. J. O'Mahony, L. Morgan, C. M. O'Connor, K. Morgan, J. A. Baugh, and S. C. Donnelly
Sarcoidosis and MIF gene polymorphism: a case-control study in an Irish population
Eur. Respir. J., February 1, 2007; 29(2): 325 - 329.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the European Respiratory Society.